Navigation Links
Trillium and Biogen Idec enter into global license agreement
Date:1/12/2010

TORONTO, Jan. 12 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into a definitive license agreement with Biogen Idec ( BIIB), granting the latter exclusive worldwide rights to one of Trillium's development programs.

"Biogen Idec is a premier biotechnology partner and a world leader in immunology research and development", commented Trillium CEO, Dr. Niclas Stiernholm. "We have had the privilege and fortune to work with some of the world's best immunology companies over the past few years, which reinforces the value and quality of our strong and innovative science."

"The Biogen Idec partnership clearly adds value and strongly validates the quality of our programs" underlined Luc Marengère, lead investor and Managing General Partner with VG Partners.

Under the terms of the agreement, TTI will receive an upfront payment and is eligible to receive milestone payments based on achievements of specified clinical, regulatory and commercial accomplishments. TTI will also receive royalties on global product sales. No other financial terms were disclosed. Biogen Idec will be solely responsible for clinical development, regulatory approvals, manufacturing and commercialization.

"Trillium's strong immunology foundation and its close connection to Toronto's world class immunology research community, has allowed it to build a suite of exciting biologies opportunities in the immunoregulatory field", added Dr. Michael Moore, Trillium's Chairman. "We look forward to concluding additional partnerships later in the year, particularly around our non-core assets."

About Trillium:

Trillium Therapeutics Inc. is a private biopharmaceutical company specializing in innovative therapies of immune-mediated conditions, such as autoimmune and inflammatory disorders, as well as cancer. The company's lead program, TTI-1612, is a recombinant growth factor that is being developed for the treatment of interstitial cystitis (IC) and the prevention of necrotizing enterocolitis (NEC). Trillium has broad portfolio preclinical immunology programs, including two that target the CD200 immunoregulatory axis; a CD200-specific monoclonal antibody for the treatment of cancer, and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases. In addition, the company has an FcyRlla-specific humanized monoclonal antibody in development for treatment of immune complex-mediated inflammatory diseases.

The company has a broad network of external academic and industry R&D collaborations, including several license agreements with major US biotechnology companies. The Company is supported by three premier venture capital investors: Vengrowth Private Equity Partners, Growthworks Capital and BDC Capital.

SOURCE Trillium Therapeutics Inc.


'/>"/>
SOURCE Trillium Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
2. Trillium Strengthens its Board of Directors
3. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
4. Biogenerics Will Save Billions, Says Hospira CEO
5. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
6. Icahn Confirms Intention to Nominate Three Directors at Biogen
7. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
8. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
9. CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years
10. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
11. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Ames, Iowa (PRWEB) , ... December 08, 2016 , ... ... of asynchronous approvals for biotech crops. The authors focus on the economic effects in ... the global approval of new biotech crops and the resultant risk of low level ...
(Date:12/8/2016)... 2016 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... and commercializing products to treat rare diseases where there ... will be hosting an Investor Webcast Event Friday, December ... of innate defense regulators (IDRs) as a new drug ... and the recently announced and published Phase 2 clinical ...
(Date:12/8/2016)... Dec. 8, 2016 Savannah River Remediation ... and selected NewTechBio,s NT-MAX Lake & Pond ... beneficial bacteria, in conjunction with Hexa Armor/ Rhombo ... with National Pollutant Discharge Elimination System requirements. ... a steady history of elevated pH levels, above ...
(Date:12/8/2016)... , Dec. 8, 2016  Partnering to fuel ... Ben Franklin Technology Partners of Southeastern Pennsylvania ... ("IHG"), the parent company of Independence Blue Cross; and ... announced their intentions for a $6 million funding initiative ... healthcare startups. Responding to a burgeoning economic ...
Breaking Biology Technology:
(Date:11/29/2016)... Nov. 29, 2016 BioDirection, a privately held ... for the objective detection of concussion and other traumatic ... successfully completed a meeting with the U.S. Food and ... test Pre-Submission Package. During the meeting company representatives reviewed ... a precursor to commencement of a planned pilot trial. ...
(Date:11/22/2016)... November 22, 2016 According to the new market ... Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact ... MarketsandMarkets, the market is expected to grow from USD 10.74 Billion in ... 16.79% between 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... it has just released a new white paper authored by Zettar that covers the ... transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a complicated endeavor ...
Breaking Biology News(10 mins):